Cargando…

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin

The hepatic carbohydrate-recognizing asialoglycoprotein receptor (ASGR1) mediates the endocytosis/lysosomal degradation of desialylated glycoproteins following binding to terminal galactose/N-acetylgalactosamine. Human heterozygote carriers of ASGR1 deletions exhibit ∼34% lower risk of coronary arte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Susan-Resiga, Delia, Girard, Emmanuelle, Essalmani, Rachid, Roubtsova, Anna, Marcinkiewicz, Jadwiga, Derbali, Rabeb M., Evagelidis, Alexandra, Byun, Jae H., Lebeau, Paul F., Austin, Richard C., Seidah, Nabil G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479480/ https://www.ncbi.nlm.nih.gov/pubmed/34508778 http://dx.doi.org/10.1016/j.jbc.2021.101177

Ejemplares similares

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity
por: Essalmani, Rachid, et al.
Publicado: (2022)

SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2
por: Essalmani, Rachid, et al.
Publicado: (2023)

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels
por: Fruchart Gaillard, Carole, et al.
Publicado: (2022)

Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9
por: Oleaga, Carlota, et al.
Publicado: (2020)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

In Vivo Analysis of the Contribution of Proprotein Convertases to the Processing of FGF23
por: Al Rifai, Omar, et al.
Publicado: (2021)

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
por: Lebeau, Paul F., et al.
Publicado: (2022)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model
por: Sun, Xiaowei, et al.
Publicado: (2009)

Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?
por: Guillemot, Johann, et al.
Publicado: (2014)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022)

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
por: Lipari, Michael T., et al.
Publicado: (2012)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
por: Seidah, Nabil G.
Publicado: (2021)

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction
por: Sawaguchi, Jun, et al.
Publicado: (2022)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Furin Is the Major Proprotein Convertase Required for KISS1-to-Kisspeptin Processing
por: Harihar, Sitaram, et al.
Publicado: (2014)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Torso-like mediates extracellular accumulation of Furin-cleaved Trunk to pattern the Drosophila embryo termini
por: Johnson, Travis K., et al.
Publicado: (2015)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Pcsk5 is required in the early cranio-cardiac mesoderm for heart development
por: Szumska, Dorota, et al.
Publicado: (2017)

Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice
por: Lebeau, Paul F., et al.
Publicado: (2019)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
por: Ochoa, Eguzkine, et al.
Publicado: (2016)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

Heparin enhances the furin cleavage of HIV‐1 gp160 peptides
por: Pasquato, A., et al.
Publicado: (2007)

Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth
por: Declercq, Jeroen, et al.
Publicado: (2015)

Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine
por: De Castro-Orós, Isabel, et al.
Publicado: (2016)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
por: Li, Li, et al.
Publicado: (2018)

23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
por: Li, Hui-hui, et al.
Publicado: (2019)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

PCSK9 Contributes to the Cholesterol, Glucose, and Insulin2 Homeostasis in Seminiferous Tubules and Maintenance of Immunotolerance in Testis
por: Pelletier, R.-Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2dptko0lnn1tipeeuusnk8q71l